GTSE1 has been revealed as a biomarker for the immunosuppressive tumor microenvironment based on a pan-cancer analyses [13], and high expression of GTSE1 is associated with poor patient survival in many cancer types, such as bladder cancer [14], acral melanoma [15], hepatocellular carcinoma [16, 17], lung cancer [18], clear cell renal cell carcinoma [19, 20], non-small-cell lung cancer [21], cervical cancer [22], and breast cancer [23]. This evidence concerns the gene GTSE1 and urinary bladder cancer.